L-DOPS

L-DOPS (also known as Droxidopa) is a synthetic amino acid that is converted by the body into norepinephrine. It is used as a prodrug and has been found to be effective in the treatment of certain conditions such as neurogenic orthostatic hypotension and Parkinson's disease.

History[edit | edit source]

L-DOPS was first developed in the 1980s by Sumitomo Pharmaceuticals, a Japanese pharmaceutical company. It was later licensed to Chelsea Therapeutics, which conducted the clinical trials necessary for approval in the United States.

Medical Uses[edit | edit source]

L-DOPS is primarily used in the treatment of neurogenic orthostatic hypotension, a condition characterized by a significant drop in blood pressure upon standing. This condition is common in patients with Parkinson's disease and other forms of dysautonomia. L-DOPS works by increasing the levels of norepinephrine in the body, which helps to maintain blood pressure.

In addition to its use in treating orthostatic hypotension, L-DOPS has also been studied for potential use in treating fibromyalgia, chronic fatigue syndrome, and attention deficit hyperactivity disorder (ADHD).

Side Effects[edit | edit source]

Like all medications, L-DOPS can cause side effects. The most common side effects include headache, dizziness, nausea, and high blood pressure. In rare cases, it can cause a condition known as pheochromocytoma, a rare tumor of the adrenal glands.

Pharmacology[edit | edit source]

L-DOPS is a prodrug, meaning it is inactive until it is metabolized by the body. Once ingested, it is converted into norepinephrine by the enzyme dopamine beta-hydroxylase. This increase in norepinephrine levels helps to maintain blood pressure and prevent the symptoms of orthostatic hypotension.